$27.25
-0.87%BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Last Annual Value
14.25M
3-Year CAGR
-12%
5-Year CAGR
18%
10-Year CAGR
60%
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() BioLife Solutions, Inc. NASDAQ:BLFS | 14.25M | -15.0% | -7.9% | 45.1% | |
![]() NovoCure Limited NASDAQ:NVCR | 9.03M | N/A | 121.6% | 4.9% | |
![]() AtriCure, Inc. NASDAQ:ATRC | 0.00 | N/A | N/A | N/A | |
![]() Neogen Corporation NASDAQ:NEOG | 44.80M | 20.6% | N/A | N/A | |
![]() Phreesia, Inc. NYSE:PHR | 72.29M | 30.4% | 23.8% | N/A | |
![]() Pulse Biosciences, Inc. NASDAQ:PLSE | 1.60M | -20.7% | 1.9% | N/A | |
![]() STAAR Surgical Company NASDAQ:STAA | 49.75M | 32.4% | 17.3% | 34.3% | |
![]() Harrow Health, Inc. NASDAQ:HROW | 59.27M | 39.9% | 119.5% | N/A | |
![]() Azenta, Inc. NASDAQ:AZTA | 114.39M | 4.9% | -6.7% | 12.6% | |
![]() Kestra Medical Technologies, Ltd. NASDAQ:KMTS | 8.49M | 22.1% | N/A | N/A |
Continue your BLFS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.